Mia's Feed
Medical News & Research

Largest Autism Inpatient Cohort Releases Genetic and Phenotypic Data for Over 1,500 Children

Largest Autism Inpatient Cohort Releases Genetic and Phenotypic Data for Over 1,500 Children

Share this article

SFARI has released a groundbreaking dataset of genetic and phenotypic data from over 1,500 hospitalized children with autism, focusing on those with profound autism. This resource aims to accelerate research and targeted interventions for individuals with high support needs.

2 min read

The Simons Foundation Autism Research Initiative (SFARI) has unveiled a comprehensive dataset comprising genetic and phenotypic information from the Autism Inpatient Collection (AIC). This cohort includes more than 1,500 children and adolescents aged 4 to 20 years, all of whom were hospitalized across six child psychiatry units in the United States. The AIC was established to focus on individuals with severe forms of autism, often characterized by intellectual disabilities or minimal verbal communication, necessitating high levels of supervision and support. These individuals are notably underrepresented in outpatient and community-based datasets.

According to Matthew Siegel of Boston Children's Hospital, who founded and leads the AIC, "This dataset is the largest single collection of information on hospitalized children with autism, many of whom meet the criteria for profound autism." The goal is to use this rich dataset, which pairs detailed behavioral and cognitive phenotypic measures with high-confidence genetic data, to accelerate research into autism, especially in children with the most urgent needs.

The data encompass key domains such as behavior, communication, emotional regulation, adaptive functioning, cognition, sleep, and parent stress and self-efficacy—offering an in-depth view of this challenging segment of the autism spectrum. Phenotypic assessments are detailed and can be reviewed in the Researcher Welcome Packet.

Biological samples, including blood or saliva when blood wasn't feasible, were collected from the children and their biological parents. These samples are stored in a centralized repository managed by SFARI. Whole-exome sequencing data derived from these samples are now accessible to researchers.

Kelsey Martin, executive vice president of autism and neuroscience at the Simons Foundation, expressed enthusiasm about the resource, highlighting its potential to improve understanding and treatment for people with high support needs. She acknowledged the contributions of participants and researchers over the past decade and emphasized that the dataset is expected to foster new discoveries in autism research.

All data and biospecimens are available for authorized use through SFARI Base, facilitating ongoing scientific advancement in understanding autism, especially in individuals with profound support requirements.

Stay Updated with Mia's Feed

Get the latest health & wellness insights delivered straight to your inbox.

How often would you like updates?

We respect your privacy. Unsubscribe at any time.

Related Articles

How Mechanical Pressure Influences Epigenetic Changes in Cancer Cells

New insights reveal how mechanical confinement within the tumor environment induces epigenetic changes in cancer cells, promoting invasion and drug resistance, highlighting the role of physical forces in tumor progression.

New Research Reveals Essential Role of Prostacyclin in Fetal Membrane Repair to Prevent Preterm Birth

New research uncovers the vital role of prostacyclin in repairing fetal membranes after rupture, offering potential avenues to prevent preterm birth.

Advances in Scarless Thyroid Surgery: Enhanced Nerve and Parathyroid Preservation with Increased Surgical Demands

A groundbreaking study compares scarless transoral thyroidectomy with traditional minimally invasive methods, highlighting improved nerve and parathyroid protection amid longer operative times and higher costs.

Innovative Approach Predicts Resistance to Bowel Cancer Treatments, Aiding Development of Smarter Drugs

Researchers from London have developed a groundbreaking tool that predicts how bowel cancer cells develop resistance to treatment, paving the way for personalized and more effective therapies. This innovation could significantly improve long-term outcomes for patients with this common cancer.